ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

durvalumab

Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.

Drug pageDurvalumab: every studyMany companies study it; this page follows only the 100 they lead. All 482 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 27, 2020100 company-led studies, 45 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca8643 open or runningphase 4since May 27, 2020Sep 14, 2012Nov 30, 2026phase 2 · NCT07081633
Bristol-Myers Squibbits history only70 open or runningphase 2since Feb 16, 2016Nov 25, 2015none ahead
AbbVieits history only20 open or runningphase 2since Feb 27, 2015Feb 27, 2015none ahead
Academic Thoracic Oncology Medical Investigators Consortiumits history only10 open or runningphase 2since Jul 22, 2016Jul 22, 2016none ahead
Advaxisits history only10 open or runningphase 2since Nov 6, 2014Nov 6, 2014none ahead
AGO Researchits history only11 open or runningphase 2since Nov 11, 2020Nov 11, 2020Jan 2028phase 2 · NCT04644289
Boston Scientificits history only11 open or runningphase 2since Sep 1, 2021Sep 1, 2021Jun 2027phase 2 · NCT05063565
Eli Lillyits history only10 open or runningphase 1since Oct 7, 2015Oct 7, 2015none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Biocompatibles UK, Daiichi Sankyo, Parexel, Apices Soluciones S.L., IQVIA Pty, Myriad Genetic Laboratories, PRA Health Sciences and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 11, 2016.

  1. May 22, 2023Phase 3 study in Liver NeoplasmsNCT05883644 · 111 enrolled · United States, France, Germany and more
  2. Jun 1, 2023Phase 3 study in Biliary Tract NeoplasmsNCT05924880 · 116 enrolled · China
  3. Jun 22, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05925530 · 142 enrolled · United States, Austria, Canada and more
  4. Jul 5, 2023Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT05943106 · 100 enrolled · United States
  5. Aug 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06008093 · 103 enrolled · United States
  6. Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularNCT06040099 · 58 enrolled · United States
  7. Oct 23, 2023Phase 3 study in Breast NeoplasmsNCT06103864 · 625 planned · United States, Argentina, Australia and more
  8. Nov 28, 2024Phase 3 study in Endometrial NeoplasmsNCT06746116 · 45 enrolled · Spain
  9. Apr 29, 2025Phase 2 study in Urinary Bladder NeoplasmsNCT06960577 · 150 planned · Australia, Brazil, Canada and more
  10. May 12, 2025Phase 3 study in Small Cell Lung CarcinomaNCT06992609 · 71 enrolled · Spain
  11. Jun 23, 2025Phase 2 study in Carcinoma, HepatocellularNCT07081633 · 114 enrolled · China, Hong Kong
  12. Jan 30, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07391670 · 40 planned · Australia, Georgia, Poland and more
  13. Sep 15, 2026Phase 3 study in GastricNCT07877818 · 140 planned · China
  14. Oct 9, 2026Phase 4 study in Muscle-Invasive Bladder Cancer (MIBC)NCT07876817 · 50 planned

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07081633
  2. Jun 30, 2027Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT04550260
  3. Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06103864
  4. Aug 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07391670

TargetBeta

CD274 →read by rule
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

The newest 60 of 86 AstraZeneca leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07876817Muscle-Invasive Bladder Cancer (MIBC)4Not yet recruitingJan 31, 202950
NCT07877818Gastric · China3RecruitingNov 1, 2029140
NCT07391670Carcinoma, Non-Small-Cell Lung · Australia, Georgia, Poland and more1RecruitingAug 30, 202740
NCT07081633Carcinoma, Hepatocellular · China, Hong Kong2Active, not recruitingNov 30, 2026114
NCT06992609Small Cell Lung Carcinoma · Spain3Active, not recruitingJun 30, 202971
NCT06960577Urinary Bladder Neoplasms · Australia, Brazil, Canada and more2RecruitingAug 30, 2028150
NCT06746116Endometrial Neoplasms · Spain3Active, not recruitingNov 30, 202845
NCT06103864Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJul 28, 2027625
NCT06040099Carcinoma, Hepatocellular · United States2Active, not recruitingJun 30, 202658
NCT06008093Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingOct 27, 2026103
NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States3Active, not recruitingJun 16, 2025100
NCT05925530Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingJan 12, 2026142
NCT05924880Biliary Tract Neoplasms · China3CompletedFeb 7, 2025116
NCT05883644Liver Neoplasms · United States, France, Germany and more3Active, not recruitingMar 30, 2026111
NCT05771480Biliary Tract Neoplasms · United States, France, Germany and more3Active, not recruitingOct 2, 2025142
NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more3Active, not recruitingSep 1, 20271,174
NCT05557838Carcinoma, Hepatocellular · China3Active, not recruitingSep 30, 2026214
NCT05498155Breast Neoplasms · United States, Australia, Austria and more2CompletedNov 20, 202450
NCT05043090Carcinoma, Renal Cell · United States, Argentina, Australia and more3Active, not recruitingDec 31, 2025148
NCT04960709Urinary Bladder Neoplasms · United States, Argentina, Austria and more3Active, not recruitingMar 2, 2026712
NCT04870112Carcinoma, Non-Small-Cell Lung · United States, New Zealand, Spain and more1TerminatedAug 30, 202318
NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more3CompletedJun 12, 2023152
NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain3CompletedJun 21, 2023101
NCT04642469Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedMay 31, 202330
NCT04550260Esophageal Squamous Cell Carcinoma · United States, Belgium, Brazil and more3Active, not recruitingJun 30, 2027640
NCT04592913Gastrointestinal Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingDec 20, 2024957
NCT04416633Unresectable Non-small Cell Lung Cancer (NSCLC) · India4CompletedOct 27, 2023100
NCT04449861Small Cell Lung Carcinoma Extensive Disease · China3CompletedMar 30, 2023166
NCT04385368Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedAug 31, 202389
NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingJul 8, 2024805
NCT04249362Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more2CompletedMar 30, 2023102
NCT04145193Colonic Neoplasms2WithdrawnMar 19, 20240
NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more2Active, not recruitingMay 6, 2025247
NCT03875235Biliary Tract Neoplasms · United States, Argentina, Bulgaria and more3Active, not recruitingAug 11, 2021810
NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedMay 15, 2026908
NCT03833154Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingOct 31, 2028724
NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more1Active, not recruitingMay 23, 2023175
NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedJul 18, 2023189
NCT03794544Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedJan 13, 202184
NCT03800134Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingNov 10, 2022825
NCT03830866Locally Advanced Cervical Cancer · United States, Brazil, Chile and more3CompletedJan 20, 2022770
NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more3Active, not recruitingSep 11, 2023724
NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more3Active, not recruitingMar 17, 20251,407
NCT03732677Urinary Bladder Neoplasms · United States, Australia, Belgium and more3Active, not recruitingApr 29, 20241,063
NCT03703297Small Cell Lung Carcinoma · United States, Argentina, Belgium and more3Active, not recruitingJan 15, 2024730
NCT03693300Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2CompletedDec 13, 2022117
NCT03682068Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJun 1, 20261,246
NCT03706690Carcinoma, Non-Small-Cell Lung · China, Hong Kong, India and more3Active, not recruitingJun 23, 2024407
NCT03519971Carcinoma, Non-Small-Cell Lung · Brazil, Czechia, Hungary and more3CompletedSep 7, 2023328
NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more1CompletedDec 31, 2020105
NCT03528694Non-Muscle Invasive Bladder Neoplasms · Australia, Austria, Belgium and more3Active, not recruitingApr 3, 20251,018
NCT03298451Carcinoma, Hepatocellular · United States, Brazil, Canada and more3Active, not recruitingAug 27, 20211,324
NCT03164616Non Small Cell Lung Cancer NSCLC · United States, Brazil, Bulgaria and more3Active, not recruitingMar 12, 20211,186
NCT03084471Diabetes Mellitus, Insulin-Dependent, 12 · United States, Canada, France and more3CompletedMar 31, 2020867
NCT03043872Small Cell Lung Carcinoma · United States, Argentina, Austria and more3Active, not recruitingJan 27, 2020987
NCT03003962Non Small Cell Lung Carcinoma NSCLC · United States, Australia, China and more3Active, not recruitingOct 27, 2022669
NCT02978482Advanced Malignancy · China1CompletedJan 28, 201826
NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more2CompletedJun 22, 202072
NCT02734004Stomach Neoplasms · United States, France, Israel and more2Active, not recruitingSep 17, 2021264
NCT02658214Small Cell Lung Carcinoma · Japan, Korea, Republic of1CompletedNov 14, 201932

How it is read

Names in the registry

  • “Durvalumab”, 55 entries
  • “MEDI4736”, 20 entries
  • “durvalumab”, 7 entries
  • “MEDI4736 (Durvalumab)”, 3 entries
  • “MEDI4736 + tremelimumab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.